Additionally, Weng et al. reported that lenvatinib enhances the efficacy of RT in HCC by inhibiting the Src/STAT3/NF-κB pathway, which mediates epithelial-mesenchymal transition and metastasis, leading to a synergistic effect [32]. Here, SRC is linked to hepatocellular carcinoma.